甲基与甲基用于预防高血压中的心血管疾病:案件是否已结束?
Anastasios Kollias1, Konstantinos G Kyriakoulis1, George S Stergiou1
1Hypertension Center STRIDE-7, School of Medicine, Third Department of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece.
概括
甲 (CTD) 和甲 (HCTZ) 在老年高血压患者中显示出类似的心血管结果. 在高风险个体中,CTD可能会带来好处,但观察到更高的低血率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 在高血压管理中,在化亚胺 (HCTZ) 和化 (CTD) 之间做出选择是有争议的.
- CTD被认为比HCTZ更有效,具有潜在的心血管益处和在慢性病中有效性.
研究的目的:
- 在高血压的老年患者中,比较CTD与HCTZ的疗效和安全性.
主要方法:
- 利尿剂比较项目是一项务实,开放的试验,比较了老年高血压患者的HCTZ和CTD等效剂量.
- 办公室血压 (BP) 和主要心血管 (CV) 事件在中位数2.4年的随访期间被监测.
主要成果:
- 在CTD和HCTZ组之间,主要心血管事件或非癌症死亡没有显著差异.
- 在以前心肌梗塞或中风的患者中,CTD显示出潜在的益处.
- 与CTD一起观察到更高的低血率,除了慢性病患者.
结论:
- 总的来说,CTD在一般高血压人群中没有显示出对HCTZ的优势.
- 在特定的高风险患者亚组中,CTD可能有益.
- 在使用CTD时,需要仔细监测低血.
相关概念视频
Antihypertensive Drugs: Thiazide-Class Diuretics
754
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
754
Heart Failure Drugs: Diuretics
424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
Hypertension IV: Drug Therapy and Lifestyle Modifications
17
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
17
Antihypertensive Drugs: Direct Renin Inhibitors
697
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
697
Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14


